In studies undertaken in the metastatic setting, HER2 status has unavoidably often been assessed on the primary tumour, which differs temporally, topologically, and potentially biologically from the metastatic tumour (Dowsett et al. 2001). This evidence concerns the gene ERBB2 and metastatic neoplasm.